Amylin Pharmaceuticals

Published Date: 04/11/2011
Category: Therapies & Markets

Research Report Decription

Amylin Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on Amylin Pharmaceuticals, Inc. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Amylin Pharmaceuticals, Inc. in the form of a SWOT analysis
• An in-depth view of the business model of Amylin Pharmaceuticals, Inc. including a breakdown and examination of key business segments
• Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Amylin Pharmaceuticals, Inc.
• Intelligence on Amylin Pharmaceuticals, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Amylin Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the Amylin Pharmaceuticals, Inc. and the factors that influence its strategies
• Track strategic initiatives of the company and latest corporate news and actions
• Assess Amylin Pharmaceuticals, Inc. as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Amylin Pharmaceuticals, Inc.’s business structure, strategy and prospects

Companies Mentioned:

Amylin Pharmaceuticals, Inc.

Paper Highlights:

Amylin Pharmaceuticals (Amylin), a biopharmaceutical company, engaged in the development of potential therapies to treat diabetes and obesity. It has developed and gained approval for Byetta and Symlin, for the treatment of diabetes. Amylin primarily operates in the US and Germany. The company is headquartered in San Diego, California, and employed about 300 people as of December 31, 2010.  The company recorded revenues of $668.8 million during the financial year (FY) ended December 2010, a decrease of 11.8% over FY2009. The operating loss of the company was $126.7 million during FY2010, as compared to the operating loss of $173.3 million in FY2009. The net loss was $152.3 million in FY2010, as compared to a net loss of $186.3 million in FY2009.